This module uses fundamental data of Lexaria Bioscience to approximate its Piotroski F score. Lexaria Bioscience F Score is determined by combining nine binary scores representing 3 distinct fundamental categories of Lexaria Bioscience Corp. These three categories are profitability, efficiency, and funding. Some research analysts and sophisticated value traders use Piotroski F Score to find opportunities outside of the conventional market and financial statement analysis.They believe that some of the new information about Lexaria Bioscience financial position does not get reflected in the current market share price suggesting a possibility of arbitrage. Check out Lexaria Bioscience Altman Z Score, Lexaria Bioscience Correlation, Lexaria Bioscience Valuation, as well as analyze Lexaria Bioscience Alpha and Beta and Lexaria Bioscience Hype Analysis.
Lexaria
Piotroski F Score
Market Cap
Enterprise Value
Price To Sales Ratio
Ptb Ratio
Days Sales Outstanding
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Average Payables
Stock Based Compensation To Revenue
Capex To Depreciation
Pb Ratio
Ev To Sales
Free Cash Flow Per Share
Roic
Inventory Turnover
Net Income Per Share
Days Of Inventory On Hand
Payables Turnover
Sales General And Administrative To Revenue
Average Inventory
Research And Ddevelopement To Revenue
Capex To Revenue
Cash Per Share
Pocfratio
Interest Coverage
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Intangibles To Total Assets
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Receivables Turnover
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Average Receivables
Revenue Per Share
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Short Term Coverage Ratios
Price Earnings Ratio
Operating Cycle
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Pretax Profit Margin
Ebt Per Ebit
Operating Profit Margin
Effective Tax Rate
Company Equity Multiplier
Long Term Debt To Capitalization
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Ebit Per Revenue
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Cash Conversion Cycle
Operating Cash Flow Sales Ratio
Days Of Inventory Outstanding
Days Of Sales Outstanding
Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Fixed Asset Turnover
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Price Sales Ratio
Return On Assets
Asset Turnover
Net Profit Margin
Gross Profit Margin
Price Fair Value
Return On Equity
Change In Cash
Free Cash Flow
Change In Working Capital
Other Cashflows From Financing Activities
Capital Expenditures
Total Cash From Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Begin Period Cash Flow
Depreciation
Other Non Cash Items
Change To Account Receivables
Stock Based Compensation
Change To Inventory
Investments
Net Borrowings
Total Cashflows From Investing Activities
Change To Operating Activities
Change To Netincome
Change To Liabilities
Issuance Of Capital Stock
Other Cashflows From Investing Activities
Total Assets
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Property Plant And Equipment Net
Net Debt
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Cash And Short Term Investments
Common Stock Total Equity
Common Stock Shares Outstanding
Liabilities And Stockholders Equity
Non Current Liabilities Total
Other Current Assets
Other Stockholder Equity
Total Liab
Property Plant And Equipment Gross
Total Current Assets
Common Stock
Short Long Term Debt Total
Current Deferred Revenue
Net Receivables
Short Term Debt
Inventory
Non Currrent Assets Other
Intangible Assets
Net Tangible Assets
Net Invested Capital
Net Working Capital
Property Plant Equipment
Short Term Investments
Accumulated Other Comprehensive Income
Capital Stock
Capital Lease Obligations
Depreciation And Amortization
Interest Expense
Other Operating Expenses
Operating Income
Ebit
Ebitda
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Income Tax Expense
Total Revenue
Gross Profit
Cost Of Revenue
Selling General Administrative
Selling And Marketing Expenses
Research Development
Net Interest Income
Net Income From Continuing Ops
Reconciled Depreciation
Net Income Applicable To Common Shares
Minority Interest
Interest Income
Probability Of Bankruptcy
At this time, Lexaria Bioscience's Net Debt To EBITDA is fairly stable compared to the past year. Cash Flow To Debt Ratio is likely to rise to 0.26 in 2025, despite the fact that Net Debt is likely to grow to (5.4 M). At this time, Lexaria Bioscience's POCF Ratio is fairly stable compared to the past year. Interest Coverage is likely to rise to 1.33 in 2025, whereas Days Sales Outstanding is likely to drop 25.03 in 2025.
At this time, it appears that Lexaria Bioscience's Piotroski F Score is Poor. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
The critical factor to consider when applying the Piotroski F Score to Lexaria Bioscience is to make sure Lexaria is not a subject of accounting manipulations and runs a healthy internal audit department. So, if Lexaria Bioscience's auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if Lexaria Bioscience's financial numbers are properly reported.
One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between Lexaria Bioscience's different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Lexaria Bioscience in a much-optimized way.
F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.
Book Value Per Share
0.0776
At this time, Lexaria Bioscience's Book Value Per Share is fairly stable compared to the past year.
Lexaria Bioscience Current Valuation Drivers
We derive many important indicators used in calculating different scores of Lexaria Bioscience from analyzing Lexaria Bioscience's financial statements. These drivers represent accounts that assess Lexaria Bioscience's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Lexaria Bioscience's important valuation drivers and their relationship over time.
The Macroaxis Fundamental Analysis modules help investors analyze Lexaria Bioscience Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lexaria Bioscience using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lexaria Bioscience Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When running Lexaria Bioscience's price analysis, check to measure Lexaria Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexaria Bioscience is operating at the current time. Most of Lexaria Bioscience's value examination focuses on studying past and present price action to predict the probability of Lexaria Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lexaria Bioscience's price. Additionally, you may evaluate how the addition of Lexaria Bioscience to your portfolios can decrease your overall portfolio volatility.